Wedbush Has Positive Forecast for AnaptysBio FY2025 Earnings

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at Wedbush lifted their FY2025 earnings per share estimates for shares of AnaptysBio in a note issued to investors on Wednesday, October 15th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings of ($1.86) per share for the year, up from their prior estimate of ($4.27). Wedbush has a "Outperform" rating and a $70.00 price objective on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. Wedbush also issued estimates for AnaptysBio's Q4 2025 earnings at $1.72 EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.88) EPS, FY2026 earnings at ($3.58) EPS, FY2027 earnings at ($3.89) EPS, FY2028 earnings at ($1.72) EPS and FY2029 earnings at $0.71 EPS.

A number of other research firms have also weighed in on ANAB. Barclays began coverage on AnaptysBio in a research note on Monday. They set an "overweight" rating and a $78.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of AnaptysBio in a research note on Wednesday, October 8th. UBS Group reiterated a "neutral" rating and set a $20.00 price objective (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. Finally, HC Wainwright lifted their price objective on AnaptysBio from $38.00 to $59.00 and gave the company a "buy" rating in a research note on Tuesday, September 30th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $54.78.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $34.40 on Friday. The stock has a 50-day simple moving average of $23.82 and a two-hundred day simple moving average of $22.70. The firm has a market capitalization of $963.20 million, a P/E ratio of -7.68 and a beta of -0.18. AnaptysBio has a fifty-two week low of $12.21 and a fifty-two week high of $36.54.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%.The company had revenue of $22.26 million during the quarter, compared to analysts' expectations of $11.55 million.

Hedge Funds Weigh In On AnaptysBio

Institutional investors and hedge funds have recently modified their holdings of the business. US Bancorp DE increased its stake in AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after buying an additional 979 shares in the last quarter. Farther Finance Advisors LLC increased its stake in AnaptysBio by 9,778.9% during the 1st quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock worth $35,000 after buying an additional 1,858 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock worth $48,000 after buying an additional 1,377 shares in the last quarter. Osaic Holdings Inc. increased its stake in AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock worth $52,000 after buying an additional 2,326 shares in the last quarter. Finally, GAMMA Investing LLC purchased a new stake in AnaptysBio during the 1st quarter worth approximately $113,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.